3. RESULTS
A total of 16,285 AF patients were on liraglutide and 1,557,935 AF
patients were not on liraglutide as of November 13, 2021. After
propensity score matching, both cohorts had a size of 16,214 patients
and their general characteristics can be seen in Table 1 .
AF patients on liraglutide were found to have a lower risk of all-cause
mortality when compared to AF patients not on liraglutide (HR 0.67, 95%
CI 0.631 - 0.711, p < 0.001). This was further supported with
Kaplan-Meier analysis and log-rank test seen in Figure 1. It
was found that survival probability was higher in patients with AF and
liraglutide (66% vs. 63.5%, p < 0.001). There also appeared
to be a lower risk for ischemic stroke, hemorrhagic stroke, acute heart
failure episode, and acute coronary episode, although it did not reach
statistical significance (Table 2 ).